TW400385B - A method of assaying cholesterol in a high density lipoprotein - Google Patents
A method of assaying cholesterol in a high density lipoprotein Download PDFInfo
- Publication number
- TW400385B TW400385B TW084103384A TW84103384A TW400385B TW 400385 B TW400385 B TW 400385B TW 084103384 A TW084103384 A TW 084103384A TW 84103384 A TW84103384 A TW 84103384A TW 400385 B TW400385 B TW 400385B
- Authority
- TW
- Taiwan
- Prior art keywords
- cholesterol
- lipoproteins
- specific gravity
- high specific
- lipoprotein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 116
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 105
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 52
- 102000015779 HDL Lipoproteins Human genes 0.000 title abstract description 54
- 108010010234 HDL Lipoproteins Proteins 0.000 title abstract description 54
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 50
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 50
- -1 polyoxyethylene Polymers 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920000447 polyanionic polymer Polymers 0.000 claims abstract description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract 5
- 229940077388 benzenesulfonate Drugs 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 18
- 230000005484 gravity Effects 0.000 claims description 17
- 238000011049 filling Methods 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 8
- 108010055297 Sterol Esterase Proteins 0.000 claims description 4
- 102000000019 Sterol Esterase Human genes 0.000 claims description 4
- 238000004898 kneading Methods 0.000 claims description 4
- 238000001952 enzyme assay Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 claims 2
- 238000004445 quantitative analysis Methods 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 210000001624 hip Anatomy 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 30
- 238000000926 separation method Methods 0.000 abstract description 3
- 150000004996 alkyl benzenes Chemical class 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 description 41
- 229940088598 enzyme Drugs 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 229930182558 Sterol Natural products 0.000 description 15
- 235000003702 sterols Nutrition 0.000 description 15
- 150000003432 sterols Chemical class 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 235000015170 shellfish Nutrition 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000002079 cooperative effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000002309 gasification Methods 0.000 description 4
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- FKWSMBAMOQCVPV-UHFFFAOYSA-N magnesium dicyanide Chemical compound [Mg+2].N#[C-].N#[C-] FKWSMBAMOQCVPV-UHFFFAOYSA-N 0.000 description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 4
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- JDEJGVSZUIJWBM-UHFFFAOYSA-N n,n,2-trimethylaniline Chemical compound CN(C)C1=CC=CC=C1C JDEJGVSZUIJWBM-UHFFFAOYSA-N 0.000 description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- 102100034866 Kallikrein-6 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- RTXGMEZVGIEEJR-UHFFFAOYSA-N [Re].[Na] Chemical compound [Re].[Na] RTXGMEZVGIEEJR-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 1
- 101100536692 Drosophila melanogaster Ten-m gene Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229920002025 Pluronic® F 88 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000221662 Sclerotinia Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WWLOCCUNZXBJFR-UHFFFAOYSA-N azanium;benzenesulfonate Chemical compound [NH4+].[O-]S(=O)(=O)C1=CC=CC=C1 WWLOCCUNZXBJFR-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SQEDZTDNVYVPQL-UHFFFAOYSA-N dodecylbenzene;sodium Chemical compound [Na].CCCCCCCCCCCCC1=CC=CC=C1 SQEDZTDNVYVPQL-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
五、發明説明(豕) 實施例3 就含脂蛋白質之檢體31〜40號依本發明方法及以往沈 澱法定量HDL中膽固醇,比較測定值,結果如表3。 即於檢體4/i 1加含磷_酸銷0.2%,氰化鎂100bM及聚 氧乙烯-聚氣丙烯縮合物(Phuronic F-88,旭電化公司) 0.2%之試藥300wl,次加與實施例1 一樣之膽固醇測 定試藥10 0W 1。以下仿S施例1求HDL中之膽固醇濃度。 另沈澱法也仿實施例1測定。 表3 (請先閲讀背面之注意事項再填寫本頁) • I · 檢體No. 膽固醇濃度(ng/d 1) 沈澱法 本發明方法 31 46 46 32 59 57 33 52 52 34 39 39 35 31 34 36 55 54 37 40 49 38 78 77 39 42 40 40 S3 52 訂 經濟部中央橾準局貝工消费合作社印東 由表3得知,本發明方法能簡便操作,仍可得與以往 沈澱法同等測定值。 10 本紙張尺度適用中國國家標準(CNS ) A4^格(210X297公嫠) 經濟部十央標準局負工消费合作杜印製 Α7 Β7 五、發明説明(1) 技術領域 本發明為有拥無霈離心分離等前處理,以簡便之操作而 高效率地定量高比重脂蛋白質中之《固醇。又可適用種 種自動分析装置,在醢床檢査上極有用。 背景技術 «固醇等脂霣乃在血淸中舆脱補基蛋白結合而形成脂 蛋白質。脂蛋白質乃依物理性狀之差異而分為乳糜脂蛋 白質(Chyloaicron),超低比重脂蛋白,低比重腊蛋白 (LDU,离比重脂蛋白(HDL),e逭些脂蛋白質中,LDL 具有動脈硬化引起性,而HDL則有抗動脈硬化作用β 疫學上證明HD L中臛固酵值舆動腯硬化性疾病之發症 頻度呈反相蘭,目前以虛血性心疾病之預防或診斷為目 的,廣泛地測定HDL中之臛固醇β 至於HDL中之膽固酵之澍定法,已知例如經超離心分 離HDL與其他脂蛋白質後,供臛固酵澜定之方法,經霣 泳分離後,将脂質染色而澜定其發色強度之方法等。但 埴些方法均操作煩雜,不能處理多數檢體之問賵,而平 常殆無使用β 作為H D L中之臛固醇剷定方法,目前饞床檢査領域一 般廣泛採用之方法乃於檢醮加沈澱劑使HDL以外之脂蛋 白質凝集,将此離心來去除,所分離之只含H DL之上淸 中之«固酵予以測定之沈澱法。 此方法雖比超離心法及電泳法簡便,佴因加沈澱劑來 分離,故須較多檢體量,且發生分析誤差之可能性也离, 本紙張尺度適用中國國家揉準(CNS ) Α4規格(210X297公釐) (请先閲讀背面之注意事項再填寫本頁) -Ι-訂 修正 補充•邮 五、發明説明(1
實施例4 就含脂蛋白質之檢體4 i〜50號依本發明方法及以往沈 澱法定悬HDL中暖固酵,比較測定值,結果如表“ 即於檢醱4wl加含磷鎢酸銷0.2%,氯化^100bM及聚 «乙嫌-十六H (Eiulgen 22Θ,花王公司)0.1%之試 藥3001/ 1,次加膽固酵g酶0.2 υ/·1,膽固醇氣化瞄0.: ΙΙ/·1·過氣化酶Θ.31Ι/·1,二磺酸丁基Ν,Ν_二甲間甲苯胺 Θ.04%» 4 按基安替比林 0.005^6 及 0.7%e_ulgen Α_6ι (花王公司)之臛固醇拥定試藥100W 1。以下仿實施例1 求HDL中之膽固酵濃度。 另沈澱法也仿實施例1測定。 表4 (請先聞讀背面之注f項再填寫本頁) 訂 經濟部中央揉率局Λ工消费合作杜印*. 檢體No. 膽固醇濃度(Bg/dl) _ -. 沈澱法 本發明方法 41 90 89 42 85 84 43 79 76 44 77 74 45 74 74 46 70 68 47 69 6S 48 62 62 49 53 59 50 49 S3 由表4得知,本發明方法能簡便操作,仍可得舆以往 沈澱法同等測定值。 -11 本紙張尺度遙用中國國家橾率(CNS ) Α4规格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(2 ) 不能將全分析程序完全自動化。 另也檢討酵素方式分別定量HDL中之膽固酵之方法, 例如己知在膽酸鹽或非離子条界面活性劑之存在下進行 酵素反應之方法(日本特两昭6 3 - 1 2 6 4 9 8號公報)„此方 法利用其反應初期之酵素反應速度與LDL濃度成比例而 其後與HDL中轚固酵瀑度成比例者,但HDL中之鼴固醇與 其他脂蛋白質中膽固酵之反應無法完全分別,所測定對 象並非LDL中轚固酵至HDL中嫌固酵成階段性,乃邊重叠 邊徐徐變化,故雞諝正確之方法》 又知将HDL以外之脂蛋白質預先凝集,僅将BDL中之轚 固醇予以酵素反應後,使酵素失活同時使凝集再溶解而 測定吸光度之方法(特開平6-242110號公報)。但此方法 須至少3次添加試藥之操作,故只適用於有限之自動分 析装置,在泛用性上有問題。又在沈澱之再溶解時用高 灌度之鹽等對分析機器之損寄及試蕖廢棄上也非滿足者。 故本發明之目的為提供無需離心等前處理,能以簡便 之操作高效率地ill定,並適用於種種自動分析装置之HDL 中β固醇之定量方法。 鑑此,本發明者們棰力研究之結果發現於檢髏添加與 HDL以外之脂蛋白質形成複合體之物質及界面活性劑後, 酵素測定膽固醇,則可高效率地定量HDL中之磨固醇,且 能適用於自動分析裝置,终於完成本發明。 發明之掲示 本發明傜一種高比重脂蛋白質中膽固醇之定量方法, 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) ^—^1- IT flm n^i nn i m· t— n· 1 1 IJAI« n^i —4 ¥ - .1 Π (諳先閲讀背面之注意事項再填寫本頁) 400385
修正 補充%W 8 A7 B7
五、發明説明(K 實施例5 躭含脂蛋白質之檢體41〜50號依本發明方法及以往沈 澱法定量HDL中腭固醇,比較測定值,結果如表5。 即於檢髏4«1加含磷鎢酸銷0.2%,氰化鎂100·Μ及聚 氣乙烯-壬基苯基醚(e*ulgen 913,花王公司)0.190之 試藥3 00 //丨,次加與實施例4 一樣之膽固醇測定試藥 100« 1。以下仿實施例1求HDL中之鼸固酵濃度。 另沈澱法位仿實施例1測定。 表 5 檢曄Ho. 膽固醇鸛度Us/dl) 沈澱法 本發明方法. 41 90 96 42 85 93 43 79 77 44 77 76 45 74 79 46 70 74 47 69 67 48 62 64 49 53 63 SO 49 51 經濟部中央揉準f工消费合作社印氧 (請先閲讀背面之注意事項再填寫本頁) 由表5得知,本發明方法能簡便操作,仍可得舆以往 沈澱法同等測定值。 -12 本紙張尺度適用中國國家標準(CNS > A4规格(2丨0X297公釐) 經濟部中夬標準局貝工消費合作杜印製 A7 B7 五、發明説明(3 ) ,聚氣乙烯-聚氣丙烯縮合物有Pluronic F88(旭電化公 司製造)等;聚氣乙烯烷基醚硫酸鹽有聚氧乙烯十二醚 硫酸筘(花王公司製造之Ε·ιι1 20C等);烷苯磺酸鹽宜為 十二基苯裹酸納。 這些界面活性劑可用一種或併用二種以上,其使用置 並無待定,惟宜舆試料混合時之濃度為0.01〜5重貴% ,尤其0.05〜1重量%。 在本發明先将舆HDL以外之脂蛋白質形成複合鼸之物 質及界面活性_加入檢體,此時可将疽些物質混合當作 同一試藥添加,或以分別試蕖添加β 次將如此添加與HDL以外之脂蛋白質形成後合鼸之物 霣及界面活性劑之檢饑直接測定β固酵,邸無須離心等 前處理。 至於臛固酵之測定方法,可用任何習知酵素式測定法 ,例如酵素試藥僳併用膽固醇酯酶及磨固酵氣化梅之方 法,及併用膽固醇酯酶及胺固醇脱氫_之方法等。其 中宜併用膽固醇酯及臛固醇氣化_之方法。 添加酵素試蕖後,測定一定時間的倍號量,求出拥定 對象之嫌固酵濃度,更為提高分析之正確度,在添加酵 素試藥後,比較一定二點時間之信號量(2黏法),求出 91固酪之濃度。 又在添加逭些酵素試蕖等後,最後檢出膽固醇之方法 無待定,有例如更併用過氣化酶及色原讎之吸光度分析 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐> ^^1- ^n» ^1.^1 nn n In tut m 1« n^i n n —an n^i IP—·--SJ (請先閲讀背面之注意事項再填寫本頁) 400385
A7 B7 五、發明説明(I丨) 實施例6 就含脂蛋白質之檢體41〜5 0號依本發明方法及以往沈 截法定量HDL中18固酵,比較測定值,結果如表6。 即於檢體4«1加含磷箱酸銷0.2%,氯化鎂100·Μ及聚 氧乙烯-十二醚硫酸銷(eBul 20C,花王公司)0.1%之 試藥30 0wl,次加與賁施例4 一樣之膽固酵測定試藥 100«1。以下仿實施例1求HDL中之»固酵濃度。 另沈鎩法也仿實施例1測定。 表6 (請先聞讀背面之注$項再填寫本頁) 經濟部中央揉率局貝工消费合作社印装 檢體Ho. 膽固醇濃度(ng/dO 沈澱法 本發明方法 41 90 93 42 85 95 43 79 79 44 77 72 45 74 79 46 70 75 47 69 66 46 62 64 49 53 65 50 49 52 由表6得知,本發明方法能_便操作,仍可得舆以往 沈截法同等測定值。 -13 - 本紙張尺度適用中國國家揉率(CNS ) A4规格(210X297公釐) 訂 A7 B7 經濟部中央標準局貝工消費合作杜印製 五、發明説明 ( 4 ) 1 1 一 其 特 歎 為 於 含 脂 蛋白質之檢 臁中 添 加 與高 比重腊 蛋白質 1 1 I 以 外 之 脂 蛋 白 質 形成複合* 之物 質 及 界面 活性劑 後,依 1 1 酵 素 澜 定 法 m 定 臛固鱒》 請 1 先 1 實 施 本 發 明 之 最 佳形態 閲 讀 1 本 發 明 所 用 輿 HDL以外之脂蛋白質形成禊合龌之物質 背 1 I 之 只 要 為 對 HDL及HDL以外之脂 蛋白 質 之 間有 親和性 差異之 注 1 1 物 質 即 可 9 例 如 聚蕕萄糖硫 酸, 磷 m 酸, 肝素等 聚陰雄 事 項 再 1 1 子 如 鎂 離 子 * 鈣離子等二 價金 羼 離 子; 如聚乙 二醇等 填 窝 本 A 水 溶 性 离 分 子 對抗HDL以外之脂蛋白質之抗«等❶這些 頁 1 I 物 質 可 用 —* 種 或 併用二種以 上, 尤 宜 併用 聚陰離 子舆二 1 1 價 金 屬 離 子 〇 1 這 些 物 質 之 用 量並無特定 ,難 視 物 霣之 種類而 異,但 訂 只 要 造 些 物 質 與 HDL以外之脂蛋白質在制定時形成複合 钃 邸 可 » 不 拘 凝 集物形成輿 否。 例 如 併用 聚陰離 子與二 1 j 價 金 羼 離 子 時 > 混合試料時 之濃 度 宜 呈聚 陰離子 0 · 02〜2 1 1 重 m % 9 二 價 金 屬離子10〜 500bM, 尤宜用形成聚陰離子 r 1 0 . 05 1 重 量 % ,二價金羼 離子 20 〜 2 0 0道 M〇 Λ 1 本 發 明 所 用 界 面活性_宜 為對 膽 固 醇之 酵素式 澜定条 1 1 有 抑 制 效 果 9 m 不溶解脂蛋 白質 者 9 諸如 聚氧乙 烯烷基 1 I 醚 聚 氣 乙 ί烷基苯基_ 聚 氧 乙 烯-聚氣丙烯縮合 1 1 ,物 聚 氧 乙 播 丨烷基醚硫酸鹽, 院 苯 磺酸 邇等。 其中 1 1 聚 氣 乙 烯 焼 基 m 可為聚氣乙 烯十 - m (HLB 1 4 )(花 王公司 1 I 製 造 之 £ η ul ge η 2 2D等);聚氣乙烯烷基苯基醚有聚氣乙 1 1 烯 壬 基 苯 基 m (H L Β 1 5 )(花王 -5 公司 製 造 之S· u 1 g e η 913 等) 1 1 1 1 1 1 本紙張尺度適用中國國家標準(CNS ) A4规格(210X 297公釐)
實施例7 就含脂蛋白質之檢體41〜50號依本發明方法及以往沈 澱法定量HDL中膽固醇,比較測定值,結果如表7。 即於檢體4wl加含璘鎢酸納0.2%,氛化鎂100 ·Μ及聚 氣乙嫌-十一院苯横酸納(Neopelex F-65,花王公司) 0.1%之試藥300« 1,次加與實施例4 一樣之膽固醇測 定試藥100W 1。以下仿實施例1求HDL中之_固酵濃度 〇 另沈澱法也仿實施例1測定。 表7 (請先閲讀背面之注意事項再填寫本頁) 訂 檢醱Ho. 膽固醇港度(》g/dl) 沈戳法. 本發明方法 41 90 82 42 85 80 43 79 74 44 77 70 45 74 75 46 70 73 47 69 64 48 62 63 49 53 66 50 49 55 經濟部中央橾準局貝工消費合作社印裝 由表7得知,本發明方法能簡便操作,仍可得與以往 沈澱法同等測定值。 -14 - 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(5 ) ,直接檢出輔醻及過氣化氬之方法等。 實施例 次舉實施例說明,但本發明並不限於渣些實施例。 實施例1 就含脂蛋白質之血淸檢體1〜10號依本發明方法及以 往沈澱法,定量HDL中之醺固酵,比較這些測定值,如 表1。 即於檢釀4;ul加含磷鎢酸納0.2%,氯化镁IOObM及聚 氣乙烯-聚氧丙烯缩合物(Pluronic F-68,旭東化公司) 0 . 5 %之試藥3 0 0 1 ,次加朦固酵酯_ 0 · 2 U / 1,明[固酵 氣化_〇.2ϋ/·1,遇氣化_0.3ϋ/·1, N,N -二甲間甲苯 胺 0.04%, 4-胺基安替比林 0.0 0 5 % 及 0.1% Triton X- 100之轚固醇測定試藥1〇〇#1後,测定在5 4 5 nm之吸光度 之差,以求出HDL中之臛固醇濃度。以上操作用日立7150 型自動分析装置〇 若依沈澱法潮定HDL中之膽固醇時,混合含聚葡萄糖 硫酸0.3%及氛化鎂2%之水溶液0.2*1及檢體0.2nl,而 以30()()γρβ離心10分。採集上淸5D# 1混合同上轚固醇測 定試藥3b1,保溫37 °C 10分後,在545η B測定吸光度, 求出HDL中之腾固醇驀度。 本紙伕尺度適用中國國家標準(CNS ) A4規格(2丨0 X 297公釐) 1^1- n n^i n^l nn HI I ^1. m n^— ml n^i \J - i (請先閲讀背面之注意事項再填寫本頁) I補充 五、發明説明(丨3) A7400385 B7 而 作 操 之 BC 簡 以 1 —1 理 處 前 等 離 分 性心 bb ttv 链 ΐΐ 可箱 用無 利, 之明 上發 業本 産依 sl_ 1 用 適 可 又 0 醇 。 固用 膽有 之極 中上 質查 白檢 蛋床 脂臨 重在 比 , 高置 董裝 定析 地分 率動 效自 高種 (請先閲讀背面之注意事項再填寫本頁)
、tT 經濟部中央揉準局貝工消费合作社印«.-
5 1X 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) A7 B7 五、發明説明(6 ) 表1 檢醱No. 膽固酵濃度(《g/d_α ) 本發明方法 沈澱法 1 79 80 2 65 64 3 64 64 4 64 58 5 15 18 6 8 1 88 7 47 48 8 38 38 9 4 7 4 6 10 33 32 tml. —^—1— fl 1^1^1 I ml n m ^i^ifl Bl nn —mmt—·nl·— 4 - i (請先閲讀背面之注意事項再填寫本頁) 經濟部中央樣準局負工消費合作社印製 由表1得知,本發明方法雖為簡便之操作,仍能獲與 習用沈澱法同等潮定值。 資施例2
就含脂蛋白質之檢釀11〜20號依本發明方法及以往沈 澱法定量HDL中臛固醇,比較澜定值,結果如表I 即於檢龌4# 1加含磷鎢酸納0.2%,聚葡萄糖硫酸1.8 克/ JI ,氯化鎂IOObM及聚氣乙烯-聚氣丙烯缩合物( -8 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 經濟部中央橾準局員工消费合作社印聚 A7 B7五、發明説明(7 ) Phuronic F-68,旭霉化公司)0.2%之試藥300#1,次加 與實施例1 一樣之«固醇測定試藥100/^1。以下仿實施 例1求HDL中之》固醇蠹度。另沈澱法也仿實施例1測定。表2 檢釀No. 膽固酵濃度Ug/d_α ) 本發明方法 沈澱法 11 47 4 5 12 38 34 13 36 3 2 14 54 52 15 26 2 2 16 93 92 17 6 1 62 18 36 32 19 5 5 50 20 75 74 由表2得知,本發明方法用較少試料,能簡便操作, 仍可得舆以往沈澱法同等測定值<» 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) l^n- nn ( ml ml ^^^1 n D n m· IJI—--aJ (請先閲讀背面之注意事項再填寫本頁)
五、發明説明(豕) 實施例3 就含脂蛋白質之檢體31〜40號依本發明方法及以往沈 澱法定量HDL中膽固醇,比較測定值,結果如表3。 即於檢體4/i 1加含磷_酸銷0.2%,氰化鎂100bM及聚 氧乙烯-聚氣丙烯縮合物(Phuronic F-88,旭電化公司) 0.2%之試藥300wl,次加與實施例1 一樣之膽固醇測 定試藥10 0W 1。以下仿S施例1求HDL中之膽固醇濃度。 另沈澱法也仿實施例1測定。 表3 (請先閲讀背面之注意事項再填寫本頁) • I · 檢體No. 膽固醇濃度(ng/d 1) 沈澱法 本發明方法 31 46 46 32 59 57 33 52 52 34 39 39 35 31 34 36 55 54 37 40 49 38 78 77 39 42 40 40 S3 52 訂 經濟部中央橾準局貝工消费合作社印東 由表3得知,本發明方法能簡便操作,仍可得與以往 沈澱法同等測定值。 10 本紙張尺度適用中國國家標準(CNS ) A4^格(210X297公嫠) 修正 補充•邮 五、發明説明(1
實施例4 就含脂蛋白質之檢體4 i〜50號依本發明方法及以往沈 澱法定悬HDL中暖固酵,比較測定值,結果如表“ 即於檢醱4wl加含磷鎢酸銷0.2%,氯化^100bM及聚 «乙嫌-十六H (Eiulgen 22Θ,花王公司)0.1%之試 藥3001/ 1,次加膽固酵g酶0.2 υ/·1,膽固醇氣化瞄0.: ΙΙ/·1·過氣化酶Θ.31Ι/·1,二磺酸丁基Ν,Ν_二甲間甲苯胺 Θ.04%» 4 按基安替比林 0.005^6 及 0.7%e_ulgen Α_6ι (花王公司)之臛固醇拥定試藥100W 1。以下仿實施例1 求HDL中之膽固酵濃度。 另沈澱法也仿實施例1測定。 表4 (請先聞讀背面之注f項再填寫本頁) 訂 經濟部中央揉率局Λ工消费合作杜印*. 檢體No. 膽固醇濃度(Bg/dl) _ -. 沈澱法 本發明方法 41 90 89 42 85 84 43 79 76 44 77 74 45 74 74 46 70 68 47 69 6S 48 62 62 49 53 59 50 49 S3 由表4得知,本發明方法能簡便操作,仍可得舆以往 沈澱法同等測定值。 -11 本紙張尺度遙用中國國家橾率(CNS ) Α4规格(210X297公釐) 400385
修正 補充%W 8 A7 B7
五、發明説明(K 實施例5 躭含脂蛋白質之檢體41〜50號依本發明方法及以往沈 澱法定量HDL中腭固醇,比較測定值,結果如表5。 即於檢髏4«1加含磷鎢酸銷0.2%,氰化鎂100·Μ及聚 氣乙烯-壬基苯基醚(e*ulgen 913,花王公司)0.190之 試藥3 00 //丨,次加與實施例4 一樣之膽固醇測定試藥 100« 1。以下仿實施例1求HDL中之鼸固酵濃度。 另沈澱法位仿實施例1測定。 表 5 檢曄Ho. 膽固醇鸛度Us/dl) 沈澱法 本發明方法. 41 90 96 42 85 93 43 79 77 44 77 76 45 74 79 46 70 74 47 69 67 48 62 64 49 53 63 SO 49 51 經濟部中央揉準f工消费合作社印氧 (請先閲讀背面之注意事項再填寫本頁) 由表5得知,本發明方法能簡便操作,仍可得舆以往 沈澱法同等測定值。 -12 本紙張尺度適用中國國家標準(CNS > A4规格(2丨0X297公釐) 400385
A7 B7 五、發明説明(I丨) 實施例6 就含脂蛋白質之檢體41〜5 0號依本發明方法及以往沈 截法定量HDL中18固酵,比較測定值,結果如表6。 即於檢體4«1加含磷箱酸銷0.2%,氯化鎂100·Μ及聚 氧乙烯-十二醚硫酸銷(eBul 20C,花王公司)0.1%之 試藥30 0wl,次加與賁施例4 一樣之膽固酵測定試藥 100«1。以下仿實施例1求HDL中之»固酵濃度。 另沈鎩法也仿實施例1測定。 表6 (請先聞讀背面之注$項再填寫本頁) 經濟部中央揉率局貝工消费合作社印装 檢體Ho. 膽固醇濃度(ng/dO 沈澱法 本發明方法 41 90 93 42 85 95 43 79 79 44 77 72 45 74 79 46 70 75 47 69 66 46 62 64 49 53 65 50 49 52 由表6得知,本發明方法能_便操作,仍可得舆以往 沈截法同等測定值。 -13 - 本紙張尺度適用中國國家揉率(CNS ) A4规格(210X297公釐) 訂
實施例7 就含脂蛋白質之檢體41〜50號依本發明方法及以往沈 澱法定量HDL中膽固醇,比較測定值,結果如表7。 即於檢體4wl加含璘鎢酸納0.2%,氛化鎂100 ·Μ及聚 氣乙嫌-十一院苯横酸納(Neopelex F-65,花王公司) 0.1%之試藥300« 1,次加與實施例4 一樣之膽固醇測 定試藥100W 1。以下仿實施例1求HDL中之_固酵濃度 〇 另沈澱法也仿實施例1測定。 表7 (請先閲讀背面之注意事項再填寫本頁) 訂 檢醱Ho. 膽固醇港度(》g/dl) 沈戳法. 本發明方法 41 90 82 42 85 80 43 79 74 44 77 70 45 74 75 46 70 73 47 69 64 48 62 63 49 53 66 50 49 55 經濟部中央橾準局貝工消費合作社印裝 由表7得知,本發明方法能簡便操作,仍可得與以往 沈澱法同等測定值。 -14 - 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I補充 五、發明説明(丨3) A7400385 B7 而 作 操 之 BC 簡 以 1 —1 理 處 前 等 離 分 性心 bb ttv 链 ΐΐ 可箱 用無 利, 之明 上發 業本 産依 sl_ 1 用 適 可 又 0 醇 。 固用 膽有 之極 中上 質查 白檢 蛋床 脂臨 重在 比 , 高置 董裝 定析 地分 率動 效自 高種 (請先閲讀背面之注意事項再填寫本頁)
、tT 經濟部中央揉準局貝工消费合作社印«.-
5 1X 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (1)
- 公告本 修正 P88 400385 :8 )8 經濟部中央榡準局貞工消费合作社印製 六、申請專利範圍 — 第84 1033 84號「膽固醇之定量方法」專利案 (88年6月1日修正) 六、申請專利範圍: 1. 一種高比重脂蛋白質中膽固醇之定量方法,其特徴爲 於含脂蛋白質之檢體中添加與高比重脂蛋白質以外之 脂蛋白質形成複合體之物質及界面活性劑後,將該檢 體利用直接酵素測定法測定膽固醇,其中與高比重脂 蛋白質以外之脂蛋白質形成褀合髋之物質爲選自聚陰 離子,二價金屬離子,水溶性高分子化合物或對高比 重脂蛋白質以外之脂蛋白質之抗體;界面活性劑爲選 自聚氧乙烯十六醚(HLB14),聚氧乙烯壬基苯基醚 (HLB 15),聚氧乙烯-聚氧丙烯縮合物,聚氧乙烯烷基 醚硫酸鹽及烷苯磺酸鹽之不溶解脂蛋白質者。 2如申請專利範圔第1項之高比重脂蛋白質中膽固醇之 定量方法,其中膽固醇之測定乃倂用膽固醇酯酶及膽 固醇氧化酶來施行。 3.如申請專利範圍第1或2項之高比重脂蛋白質中膽固 醇之定量方法,其中該不溶解脂蛋白質之界面活性劑 係聚氧乙烯-聚氧丙烯縮合物。 (請先Η讀背面之注項再填 ! - I I— H— :ί«, Μ, 本紙張尺度逍用中固两家揉率(CNS ) A4规格(210X297公釐) 公告本 修正 P88 400385 :8 )8 經濟部中央榡準局貞工消费合作社印製 六、申請專利範圍 — 第84 1033 84號「膽固醇之定量方法」專利案 (88年6月1日修正) 六、申請專利範圍: 1. 一種高比重脂蛋白質中膽固醇之定量方法,其特徴爲 於含脂蛋白質之檢體中添加與高比重脂蛋白質以外之 脂蛋白質形成複合體之物質及界面活性劑後,將該檢 體利用直接酵素測定法測定膽固醇,其中與高比重脂 蛋白質以外之脂蛋白質形成褀合髋之物質爲選自聚陰 離子,二價金屬離子,水溶性高分子化合物或對高比 重脂蛋白質以外之脂蛋白質之抗體;界面活性劑爲選 自聚氧乙烯十六醚(HLB14),聚氧乙烯壬基苯基醚 (HLB 15),聚氧乙烯-聚氧丙烯縮合物,聚氧乙烯烷基 醚硫酸鹽及烷苯磺酸鹽之不溶解脂蛋白質者。 2如申請專利範圔第1項之高比重脂蛋白質中膽固醇之 定量方法,其中膽固醇之測定乃倂用膽固醇酯酶及膽 固醇氧化酶來施行。 3.如申請專利範圍第1或2項之高比重脂蛋白質中膽固 醇之定量方法,其中該不溶解脂蛋白質之界面活性劑 係聚氧乙烯-聚氧丙烯縮合物。 (請先Η讀背面之注項再填 ! - I I— H— :ί«, Μ, 本紙張尺度逍用中固两家揉率(CNS ) A4规格(210X297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7013607A JP2799835B2 (ja) | 1995-01-31 | 1995-01-31 | コレステロールの定量方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW400385B true TW400385B (en) | 2000-08-01 |
Family
ID=11837925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084103384A TW400385B (en) | 1995-01-31 | 1995-04-08 | A method of assaying cholesterol in a high density lipoprotein |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5773304A (zh) |
| EP (1) | EP0753583B1 (zh) |
| JP (1) | JP2799835B2 (zh) |
| KR (1) | KR100346658B1 (zh) |
| CN (1) | CN1072724C (zh) |
| AT (1) | ATE197070T1 (zh) |
| AU (1) | AU696681B2 (zh) |
| CA (1) | CA2185562A1 (zh) |
| DE (1) | DE69519160T2 (zh) |
| DK (1) | DK0753583T3 (zh) |
| ES (1) | ES2153030T3 (zh) |
| GR (1) | GR3035274T3 (zh) |
| MX (1) | MX9604514A (zh) |
| PT (1) | PT753583E (zh) |
| TW (1) | TW400385B (zh) |
| WO (1) | WO1996023902A1 (zh) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962340A (en) * | 1994-11-02 | 1999-10-05 | Wako Pure Chemical Industries Ltd. | Homogeneous immunoassay method utilizing 5-300 mM magnesium |
| ES2165947T3 (es) | 1995-07-21 | 2002-04-01 | Wako Pure Chem Ind Ltd | Metodo para medir la cantidad de un constituyente contenido en una lipoproteina especifica. |
| JP3193634B2 (ja) * | 1996-05-29 | 2001-07-30 | 第一化学薬品株式会社 | Ldlコレステロールの定量方法 |
| ATE304608T1 (de) | 1996-12-09 | 2005-09-15 | Denka Seiken Kk | Verfahren zur bestimmung des cholesteringehalts von high-density-lipoproteinen |
| CA2344055C (en) * | 1998-09-18 | 2010-08-17 | Kyowa Medex Co., Ltd. | Method for fractional determination of cholesterol in lipoproteins and a reagent therefor |
| US20020188315A1 (en) * | 1998-12-31 | 2002-12-12 | Guzman Jose F. | Gel tourniquet cuff |
| EP1148142B1 (en) | 1999-01-20 | 2008-02-27 | Kyowa Medex Co., Ltd. | Method for quantitating triglyceride in lipoprotein |
| JP3441993B2 (ja) * | 1999-01-27 | 2003-09-02 | 松下電器産業株式会社 | コレステロールセンサ |
| CA2366663A1 (en) * | 1999-03-24 | 2000-09-28 | Mitsuaki Yamamoto | Method for quantitating cholesterol |
| CN1167809C (zh) | 1999-06-21 | 2004-09-22 | 第一化学药品株式会社 | 以游离型胆固醇为底物的酶的反应促进物质 |
| JP3686326B2 (ja) | 2000-11-08 | 2005-08-24 | アークレイ株式会社 | 高密度リポタンパク質(hdl)コレステロール測定用試験片 |
| MXPA03004206A (es) | 2000-11-14 | 2003-09-22 | Daiichi Pure Chemicals Co Ltd | Metodo de ensayo de lipido y reactivo para su uso en el mismo. |
| US6898728B2 (en) * | 2001-09-25 | 2005-05-24 | Sun Microsystems, Inc. | System domain targeted, configurable interconnection |
| ATE384135T1 (de) | 2002-01-30 | 2008-02-15 | Denka Seiken Kk | Verfahren zur quantifizierung von cholesterin in hd-(high density)-lipoprotein und reagenszusammensetzungen |
| EP1555326B1 (en) * | 2002-10-16 | 2009-11-25 | Kyowa Medex Co., Ltd. | Method and reagent for measuring cholesterol in high density lipoproteins |
| AU2003301324A1 (en) * | 2002-10-16 | 2004-05-04 | Kyowa Medex Co., Ltd. | Method and reagent for measuring cholesterol in high-density lipoproteins |
| US20050032141A1 (en) * | 2003-07-17 | 2005-02-10 | Dimagno Theodore John | Dry analytical element for high-density lipoprotein cholesterol quantification |
| US7435577B2 (en) * | 2004-02-03 | 2008-10-14 | Polymer Technology Systems, Inc. | Direct measurement of chlolesterol from low density lipoprotein with test strip |
| US7625721B2 (en) | 2004-02-03 | 2009-12-01 | Polymer Technology Systems, Inc. | Non-precipitating bodily fluid analysis system |
| CN1918303A (zh) * | 2004-04-15 | 2007-02-21 | 协和梅迪克斯株式会社 | 高密度脂蛋白中胆甾醇的测定方法 |
| WO2006033733A1 (en) * | 2004-08-17 | 2006-03-30 | Polymer Technology Systems, Inc. | Bodily fluid analysis system |
| US20060062690A1 (en) | 2004-08-17 | 2006-03-23 | Polymer Technology Systems, Inc. | Apparatus and method of manufacturing bodily fluid test strip |
| US8119360B2 (en) * | 2005-02-14 | 2012-02-21 | Kyowa Medex Co., Ltd. | Method, reagent and kit for determination of cholesterol in remnant-like particles (RLP) |
| TWI372783B (en) * | 2005-04-27 | 2012-09-21 | Kyowa Medex Co Ltd | A process for measuring the cholesterol in high density lipoprotein |
| CN100365409C (zh) * | 2005-06-01 | 2008-01-30 | 王贤理 | 一种测定低密度脂蛋白胆固醇的试剂及制备方法 |
| WO2007007392A1 (ja) | 2005-07-11 | 2007-01-18 | Wako Pure Chemical Industries, Ltd. | 新規ポリマー及びこれを用いたコレステロール測定法 |
| JP4884012B2 (ja) * | 2006-01-25 | 2012-02-22 | シスメックス株式会社 | 高密度リポタンパク質中コレステロール測定試薬キット及び測定方法 |
| GB0609493D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | Cholesterol sensor |
| GB0609494D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | HDL cholesterol sensor using specific surfactant |
| AU2008261868B2 (en) * | 2007-06-08 | 2014-03-13 | Quest Diagnostics Investments Llc | Lipoprotein analysis by differential charged-particle mobility |
| US8247235B2 (en) | 2007-06-08 | 2012-08-21 | Quest Diagnostics Investments Incorporated | Lipoprotein analysis by differential charged-particle mobility |
| US9354200B1 (en) | 2008-08-07 | 2016-05-31 | Quest Diagnostics Investments Incorporated | Detection apparatus for differential-charged particle mobility analyzer |
| US20120107850A1 (en) * | 2009-07-15 | 2012-05-03 | Panasonic Corporation | Analysis reagent and analysis device having the analysis reagent carried therein |
| JP5813284B2 (ja) | 2009-10-26 | 2015-11-17 | デンカ生研株式会社 | ApoE−containingHDL中コレステロールの測定方法 |
| WO2012011563A1 (ja) * | 2010-07-23 | 2012-01-26 | デンカ生研株式会社 | 高密度リポタンパク質3中のコレステロールの定量方法 |
| JP5671029B2 (ja) * | 2010-07-23 | 2015-02-18 | デンカ生研株式会社 | 高密度リポタンパク質3中のコレステロールの定量方法 |
| US9250211B2 (en) | 2010-12-30 | 2016-02-02 | Quest Diagnostics Investments Incorporated | Magnetic separation of lipoproteins using dextran sulfate |
| US9080201B2 (en) | 2011-03-16 | 2015-07-14 | Kyowa Medex Co., Ltd. | Method for measuring cholesterol in HDL subfraction, and reagents and kit therefor |
| CN110042146B (zh) | 2011-11-11 | 2023-09-01 | 雅培快速诊断国际无限公司 | 血样本的化验方法 |
| JP6054051B2 (ja) | 2012-04-11 | 2016-12-27 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロール(−c)の亜分画定量方法 |
| EP2891718B1 (en) | 2012-08-31 | 2019-01-30 | Kyowa Medex Co., Ltd. | Method for measuring cholesterol in high-density lipoprotein |
| ES2765475T3 (es) * | 2014-08-12 | 2020-06-09 | Shino Test Corp | Proceso de producción de una solución de sustrato para medir la actividad lipasa y método de simplificación de la producción |
| CN105137099A (zh) * | 2015-09-08 | 2015-12-09 | 长春理工大学 | 一种用次血红素六肽测定血清总胆固醇方法 |
| CN120118970A (zh) * | 2023-12-08 | 2025-06-10 | 南京晶捷生物科技有限公司 | 总胆固醇检测复合酶液、检测试纸和检测系统 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2128670B2 (de) * | 1971-06-09 | 1977-06-30 | Merck Patent Gmbh, 6100 Darmstadt | Immunologische isoenzym-bestimmungsmethode |
| CH582884A5 (zh) * | 1973-12-10 | 1976-12-15 | Hoffmann La Roche | |
| US4226713A (en) * | 1978-04-24 | 1980-10-07 | Goldberg Jack M | Diagnostic agents |
| US4215993A (en) * | 1978-12-04 | 1980-08-05 | Data Medical Associates, Inc. | Precipitating reagent and method for isolation and determination of high density lipoproteins in human serum |
| US4210557A (en) * | 1978-12-15 | 1980-07-01 | Beckman Instruments, Inc. | Non-high density lipoprotein precipitant |
| FR2513766B1 (fr) * | 1981-09-28 | 1985-09-13 | Biomerieux Sa | Procedes et reactifs de separation selective des lipoproteines de faible densite ldl et de quantification de leurs composants |
| US4946796A (en) * | 1982-01-05 | 1990-08-07 | International Institute Of Cellular & Molecular Pathology | Method of immunoassay |
| DE3338836A1 (de) * | 1983-10-26 | 1985-05-09 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung |
| EP0229767B1 (en) * | 1985-03-18 | 1990-09-26 | Royal Free Hospital School Of Medicine | Improvements relating to the detection of viruses and antibodies |
| JPS6242110A (ja) * | 1985-08-20 | 1987-02-24 | Fujitsu Ltd | 露光装置 |
| DE3636851A1 (de) * | 1986-10-29 | 1988-05-11 | Boehringer Mannheim Gmbh | Verfahren und reagenz zur spezifischen bestimmung des cholesterins der hdl-fraktion |
| US5215886A (en) * | 1987-06-22 | 1993-06-01 | Patel P Jivan | HDL determination in whole blood |
| US4900662A (en) * | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
| US5030555A (en) * | 1988-09-12 | 1991-07-09 | University Of Florida | Membrane-strip reagent serodiagnostic apparatus and method |
| DE3929032C2 (de) * | 1989-09-01 | 1998-09-03 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von HDL-Cholesterin mittels eines Schnelldiagnostikums mit integriertem Fraktionierschritt |
| US5403745A (en) * | 1990-04-27 | 1995-04-04 | Genzyme Corporation | Determination of analytes in biological fluids in the presence of substances interfering with assays therefor |
| US5286626A (en) * | 1991-12-13 | 1994-02-15 | Actimed Laboratories, Inc. | Process and apparatus for direct determination of low density lipoprotein |
| JP3107474B2 (ja) * | 1993-02-17 | 2000-11-06 | 国際試薬株式会社 | リポ蛋白分画中の成分の定量方法 |
-
1995
- 1995-01-31 JP JP7013607A patent/JP2799835B2/ja not_active Expired - Lifetime
- 1995-04-03 EP EP95913411A patent/EP0753583B1/en not_active Expired - Lifetime
- 1995-04-03 AU AU20852/95A patent/AU696681B2/en not_active Ceased
- 1995-04-03 MX MX9604514A patent/MX9604514A/es unknown
- 1995-04-03 KR KR1019960704881A patent/KR100346658B1/ko not_active Expired - Fee Related
- 1995-04-03 AT AT95913411T patent/ATE197070T1/de not_active IP Right Cessation
- 1995-04-03 DE DE69519160T patent/DE69519160T2/de not_active Expired - Lifetime
- 1995-04-03 WO PCT/JP1995/000641 patent/WO1996023902A1/ja not_active Ceased
- 1995-04-03 CN CN95192343A patent/CN1072724C/zh not_active Expired - Fee Related
- 1995-04-03 ES ES95913411T patent/ES2153030T3/es not_active Expired - Lifetime
- 1995-04-03 CA CA002185562A patent/CA2185562A1/en not_active Abandoned
- 1995-04-03 DK DK95913411T patent/DK0753583T3/da active
- 1995-04-03 US US08/704,681 patent/US5773304A/en not_active Expired - Lifetime
- 1995-04-03 PT PT95913411T patent/PT753583E/pt unknown
- 1995-04-08 TW TW084103384A patent/TW400385B/zh not_active IP Right Cessation
-
2001
- 2001-01-18 GR GR20010400091T patent/GR3035274T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5773304A (en) | 1998-06-30 |
| DE69519160T2 (de) | 2001-05-17 |
| EP0753583A4 (en) | 1997-12-10 |
| JPH08201393A (ja) | 1996-08-09 |
| KR100346658B1 (ko) | 2002-11-23 |
| DK0753583T3 (da) | 2000-11-13 |
| ATE197070T1 (de) | 2000-11-15 |
| ES2153030T3 (es) | 2001-02-16 |
| CA2185562A1 (en) | 1996-08-08 |
| AU2085295A (en) | 1996-08-21 |
| MX9604514A (es) | 1997-12-31 |
| WO1996023902A1 (en) | 1996-08-08 |
| DE69519160D1 (de) | 2000-11-23 |
| EP0753583A1 (en) | 1997-01-15 |
| AU696681B2 (en) | 1998-09-17 |
| EP0753583B1 (en) | 2000-10-18 |
| PT753583E (pt) | 2001-03-30 |
| KR970701789A (ko) | 1997-04-12 |
| CN1145096A (zh) | 1997-03-12 |
| JP2799835B2 (ja) | 1998-09-21 |
| GR3035274T3 (en) | 2001-04-30 |
| CN1072724C (zh) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4428863B2 (ja) | リポ蛋白中のコレステロールの分別定量方法および定量用試薬 | |
| JP2799835B2 (ja) | コレステロールの定量方法 | |
| TW469345B (en) | Quantitative method of LDL cholesterol | |
| KR101394802B1 (ko) | 소립자 저비중 리포 단백의 정량 시약 | |
| JPWO2000017388A1 (ja) | リポ蛋白中のコレステロールの分別定量方法および定量用試薬 | |
| JP5548733B2 (ja) | 小粒子低比重リポ蛋白の定量方法および定量キット | |
| JP6869300B2 (ja) | small,dense LDLコレステロールの定量方法およびキット | |
| JPH07301636A (ja) | 高密度リポ蛋白中のコレステロールの定量法 | |
| CN101551399A (zh) | 高密度脂蛋白胆固醇和低密度脂蛋白胆固醇定量法 | |
| US6818414B1 (en) | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same | |
| CA2597792C (en) | Method, reagent and kit for determination of cholesterol in remnant-like particles (rlp) | |
| CN117805363B (zh) | 消除血清血浆样本检测差异的小分子检测方法及试剂盒 | |
| AU2324301A (en) | Method and reagent for determination of cholesterol in remnant-like particles | |
| JP5191236B2 (ja) | 低密度リポ蛋白中トリグリセリドの測定方法及び測定用キット | |
| TW200528717A (en) | A method, reagent and kit for the quantitative analysis of the cholesterol in the very-low-density lipoprotein remnant(vldl remnant) | |
| JPWO2004055204A1 (ja) | 低密度リポ蛋白中コレステロールのマルチ定量法 | |
| JP2000116400A (ja) | リポ蛋白中のコレステロールの定量法 | |
| JP3677452B2 (ja) | リポ蛋白質に含有されるトリグリセリドの測定のための手続および診断用製品 | |
| JPWO2000057191A1 (ja) | コレステロールの定量法 | |
| JP3446486B2 (ja) | リポタンパク中の成分の測定法 | |
| KR20010108370A (ko) | 콜레스테롤의 정량법 | |
| JPWO1998059068A1 (ja) | 生体試料成分中の物質の分析方法及びこれに用いられる試薬 | |
| JP2007295935A (ja) | コレステロールの定量法 | |
| JP7455674B2 (ja) | キットおよび方法 | |
| JPH1130617A (ja) | Ldl−コレステロール測定法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |